Literature DB >> 11862421

Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells.

Mariko Kawakami1, Koji Kawakami, Raj K Puri.   

Abstract

Interleukin 13 receptor (IL-13R)-targeted cytotoxin, IL13-PE38QQR, composed of IL-13 and a mutated form of Pseudomonas exotoxin (PE), is found to be highly and specifically cytotoxic to human solid cancer cell lines. However, the mechanism of tumor cell death mediated by IL-13 toxin is still not known. To elucidate the mechanism, we utilized four head and neck cancer cell lines (SCC-25, HN12, KCCT873, and YCUM911), which express high levels of IL-13R, and IL-13 toxin is highly cytotoxic to these cells. We observed chromatin condensation and DNA fragmentation, indicating apoptotic cell death, after treatment with IL-13 toxin, as determined by bis-benzimide staining and DNA ladder assays. However, IL-13 did not induce cell death. Flow cytometric analysis suggested that these cancer cell lines increased the sub-G1/G0 phase DNA population in a dose- and time-dependent manner (ranged between 10 and 30%) after treatment with IL-13 toxin. By Western blot analysis, cleavage of caspase-3 and PARP was observed after treatment with a high concentration of IL-13 toxin, also suggesting apoptotic cell death. In addition, the results of immunofluorescence and RT-PCR assays showed that the apoptosis-regulator, Bcl-2 was downregulated after treatment with IL-13 toxin, while Bax was upregulated. Moreover, significant nitrite production was detected in the HN12 cell line after treatment with IL-13 toxin for 48--96 h. Taken together, our results suggest that IL-13 toxin-induced cytotoxicity is at least partially mediated by the apoptosis and nitric oxide pathways. This information may be useful in developing specific approaches where apoptotic bodies from tumor cells may be used to pulse antigen-presenting cells for immunotherapy of cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11862421     DOI: 10.1007/s00262-001-0242-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  5 in total

1.  Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of Th1- and Th2-type pulmonary granuloma fibroblasts.

Authors:  Claudia Jakubzick; Esther S Choi; Steven L Kunkel; Bharat H Joshi; Raj K Puri; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

Review 2.  Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis.

Authors:  Claudia Jakubzick; Steven L Kunkel; Raj K Puri; Cory M Hogaboam
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 3.  Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.

Authors:  Dennis J Yoon; Christina T Liu; Devin S Quinlan; Parsa M Nafisi; Daniel T Kamei
Journal:  Ann Biomed Eng       Date:  2011-02-25       Impact factor: 3.934

4.  Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.

Authors:  Meenu Jain; Lisa Zhang; Mei He; Erin E Patterson; Naris Nilubol; Antonio T Fojo; Bharat Joshi; Raj Puri; Electron Kebebew
Journal:  Cancer       Date:  2012-05-08       Impact factor: 6.860

5.  Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia.

Authors:  Claudia Jakubzick; Esther S Choi; Kristin J Carpenter; Steven L Kunkel; Holly Evanoff; Fernando J Martinez; Kevin R Flaherty; Galen B Toews; Thomas V Colby; William D Travis; Bharat H Joshi; Raj K Puri; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.